Protagonist Therapeutics Stock In The News
| PTGX Stock | USD 44.95 0.12 0.27% |
Our overall analysis of Protagonist Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Protagonist Therapeutics. The specific impact of Protagonist Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Protagonist Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Protagonist Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Protagonist Therapeutics Backtesting and Protagonist Therapeutics Hype Analysis. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.
Protagonist |
Protagonist Therapeutics Today Top News and Investor Outlook
Protagonist Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Protagonist and other traded companies coverage with news coverage. We help investors stay connected with Protagonist headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Protagonist Stock performance. Please note that trading solely based on the Protagonist Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Protagonist Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Protagonist earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Protagonist Therapeutics that are available to investors today. That information is available publicly through Protagonist media outlets and privately through word of mouth or via Protagonist internal channels. However, regardless of the origin, that massive amount of Protagonist data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protagonist Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protagonist Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protagonist Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protagonist Therapeutics alpha.
Protagonist Largest EPS Surprises
Earnings surprises can significantly impact Protagonist Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2018-08-07 | 2018-06-30 | -0.35 | -0.41 | -0.06 | 17 | ||
2018-05-09 | 2018-03-31 | -0.29 | -0.36 | -0.07 | 24 | ||
2024-08-06 | 2024-06-30 | -0.6 | -0.5 | 0.1 | 16 | ||
2019-11-06 | 2019-09-30 | -0.71 | -0.61 | 0.1 | 14 | ||
2019-03-12 | 2018-12-31 | -0.47 | -0.57 | -0.1 | 21 |
Protagonist Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Protagonist Therapeutics Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
27th of November 2024
Disposition of 16000 shares by Molina Arturo Md of Protagonist Therapeutics at 44.83 subje... at MacroaxisInsider
22nd of November 2024
Truist maintains Buy on PTGX with 60 target at investing.com
19th of November 2024
Protagonist Therapeutics chief medical officer sells 78,107 in stock at investing.com
15th of November 2024
Disposition of 1906 shares by Molina Arturo Md of Protagonist Therapeutics at 40.98 subjec... at thelincolnianonline.com
7th of November 2024
Protagonist Therapeutics Inc Q3 2024 Earnings EPS Loss of 0. ... at gurufocus.com
5th of November 2024
Vanguard Group Incs Strategic Acquisition in Protagonist Therapeutics Inc at gurufocus.com
18th of October 2024
Protagonist Therapeutics Inc. Advancing Treatments for Autoimmune Diseases at finance.yahoo.com
15th of October 2024
Protagonist Therapeutics is on the Move, Heres Why the Trend Could be Sustainable at finance.yahoo.com
9th of September 2024
Despite shrinking by US82m in the past week, Protagonist Therapeutics shareholders are sti... at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagonist Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagonist Therapeutics' short interest history, or implied volatility extrapolated from Protagonist Therapeutics options trading.
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.